Last reviewed · How we verify

Lower Bupivacaine Concentration

University of Chile · FDA-approved active Small molecule

Lower concentration bupivacaine reduces systemic toxicity while maintaining local anesthetic efficacy through decreased plasma levels of the active agent.

Lower concentration bupivacaine reduces systemic toxicity while maintaining local anesthetic efficacy through decreased plasma levels of the active agent. Used for Local and regional anesthesia with reduced systemic toxicity risk.

At a glance

Generic nameLower Bupivacaine Concentration
SponsorUniversity of Chile
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that blocks sodium channels in nerve fibers. By formulating it at lower concentrations, the drug achieves therapeutic local anesthetic effects with reduced risk of central nervous system and cardiac toxicity that can occur with higher systemic exposure. This approach maintains clinical efficacy for regional anesthesia while improving the safety profile.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: